Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 2449 - 2456 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC7007 | Anisomycin |
|
Protein synthesis inhibitor (blocks translation). Potent activator of stress-activated protein kinases (JNK/SAPK) and p38 MAP kinase. Acts as a potent signaling agonist to selectively elicit homologous desensitization of immediate early gene induction (c-fos, fosB, c-jun, junB and junD).
|
|
| BCC7008 | Ochratoxin A |
|
Mycotoxin that increases activity of the endoplasmic reticulum ATP-dependent calcium pump. Induces JNK activation and apoptosis in MDCK-C7 cells at nanomolar concentrations. Stimulates lipid peroxidation.
|
|
| BCC7009 | Loreclezole hydrochloride |
|
Subtype-selective GABA<sub>A</sub> receptor modulator. Acts as a positive allosteric modulator of <span class='symbol'>β</span>2 or <span class='symbol'>β</span>3-subunit containing receptors. Also acts as a negative modulator at a novel regulatory site, enhancing GABA<sub>A</sub> receptor sensitization. Inhibits homomeric <span class='symbol'>ρ</span>1 GABA<sub>C</sub> receptors.
|
|
| BCC7010 | CI 966 hydrochloride |
|
Selective inhibitor of the GABA transporter GAT-1 (IC<sub>50</sub> values are 0.26 and 1.2 <span class='symbol'>μ</span>M at cloned human and rat GAT-1 respectively). Displays over 200-fold selectivity over GAT-2 and GAT-3. Centrally active upon systemic administration <em>in vivo</em>. Anticonvulsive and neuroprotective.
|
|
| BCC7011 | Abn-CBD |
|
Neurobehaviorally inactive cannabinoid that acts as a selective agonist for GPR55 (EC<sub>50</sub> values are 2.5, >30 and >30 <span class='symbol'>μ</span>M at GPR55, CB<sub>1</sub> and CB<sub>2</sub> receptors respectively). Increases phosphorylation of protein kinases in, and migration of, human umbilical vein endothelial cells.
|
|
| BCC7012 | (S)-3,4-DCPG |
|
Potent, selective mGlu<sub>8a</sub> agonist (EC<sub>50</sub> = 31 nM). Displays > 100-fold selectivity over mGlu<sub>1-7</sub> and displays little or no activity at NMDA and kainate receptors. Increases c-Fos expression in stress-related brain areas following systemic administration in mice <em>in vivo</em>. Also potent anticonvulsant in mice <em>in vivo</em>.Caged (<em>S</em>)-3,4-DCPG, (<em>RS</em>)-3,4-DCPG and (<em>R</em>)-3,4-DCPG also available.
|
|
| BCC7013 | BW-B 70C |
|
Potent, selective inhibitor of 5-lipoxygenase. Long half-life and high oral bioavailability <em>in vivo</em>.
|
|
| BCC7014 | Ciglitazone |
|
Selective agonist at PPAR<span class='symbol'>γ</span> (peroxisome proliferator-activated receptor <span class='symbol'>γ</span>). Activates PPAR<span class='symbol'>γ</span> with an EC<sub>50</sub> value of 3 <span class='symbol'>μ</span>M <em>in vitro</em>, and is at least 33-fold selective over PPAR<span class='symbol'>α</span> and <span class='symbol'>δ</span>. Antihyperglycemic <em>in vivo</em>.
|
|